# Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

> **NCT05126433** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Urothelial Cancer
- Poorly Differentiated Neuroendocrine Carcinomas
- Homologous Recombination Deficient-Positive Malignancies Agnostic

## Interventions

- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT05126433
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-03
- **Primary completion:** 2023-12-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Termination of this study was a business decision made during portfolio review.
- **Last updated:** 2025-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126433, "Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05126433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*